New analysis suggests treatment with Tracleer® (bosentan)
is associated with improved survival in primary pulmonary
hypertension patients
Results
provide additional hope for treating PAH, a life-threatening
condition
Page
1
ALLSCHWIL/BASEL,
SWITZERLAND - 19 May 2003 - Actelion Ltd (SWX: ATLN) today
announced the analysis of long-term follow-up data of primary
pulmonary hypertension patients from Tracleer pivotal registration
studies. This data suggests that the use of this oral dual
endothelin receptor antagonist is associated with improved
survival.
Analysis
of the data at 36 months found a survival rate of 86 % for
patients treated with Tracleer compared to a predicted survival
rate of 48 % 1. The difference between observed and predicted
values at 6, 12, 24 and 36 months were statistically significant
(p<0.001) and in favor of treatment with Tracleer .
The
data presented in the recently published ATS abstract was
based upon 26-month data. In a subsequent analysis over
a longer time period, additional long-term data of up to
36 months was generated.
These
updated results of this first retrospective analysis were
presented today at the annual American Thoracic Society
meeting in Seattle, Washington, USA by Dr. Vallerie McLaughlin
from RUSH-Presbyterian-St. Luke's Medical Center in Chicago.
